Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Take a look at LBIO
Trading 30% below its 52 week high with updates coming in June.
I have been buying the dips.
I'm in here with a solid position now at 10.38 average.
IMNP
Sorry, it's my dyslexia
Just bought more INMP with my CTIC profits
Just sold my CTIC position for $1.85 for a nice gain.
I'm playing for a bounce back up today. The markets are red overseas.
Oil going up IMHO.
I just jumped in at $3.10
LBIO
Picking some up this morning on the dip!!
ONTY
This one has been a rock star.
Looks like it still has room to run
Awesome job once again!!!
I bought back my CTIC shares at 1.7274 yesterday.
Rolled some IMNP profits into here as well today
Sold IMNP for a 10% gain
Agree
She's going to run, give her some line!!!
I'm thinking of buying back my CTIC shares.
Seems oversold
I just bought s nice block at 3.28
Looking for s nice easy 10% bump
It really took off.
Still a lot of up side here I think
Yes
Thanks for the heads up.
I got in yesterday right at $2
ARNI
Should jump back in the black today and continue to climb into presentation on May 30.
Data looks great. Should easily be over $1
Great buying opportunity here in the .80's IMO
Thanks
I'm looking at it now
Yes
It really took off!
Thanks but I guess I sold too soon.
Still, it was a nice gain!
ONTY
Out at 1.81 from average entry at 1.44 for a nice gain.
Just bought more ARNI and TPIV
Not sure why it's down this AM?
ONTY
Selling at 1.60 AH
Awesome!!
Great price
Good luck to us
I agree
I just bought some back at 5.05
Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave Collaboration with Takeda Pharmaceuticals
11 hours 12 minutes ago - DJNF
SAN DIEGO, May 12, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave(R) (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, and an update on its Contrave collaboration with Takeda Pharmaceuticals Company.
This morning we and Takeda announced termination of the Light Study. We agreed with our partner, and together discussed our preferences with the U.S. Food and Drug Administration (FDA), that it was best to conclude the study in an orderly fashion, search for and gather all CV events and other safety data, have the CV events properly adjudicated, carefully analyze the final data and have these data presented and published in a scientific forum.
Since continuation of the Light Study was not a postmarketing requirement (PMR), and the majority of patients are no longer on blinded study drug, Orexigen had long advocated shutting down the study in December 2014, corresponding with the time of the 50% interim analysis, and focusing resources on new studies to further evaluate the therapeutic profile of Contrave.
We are pleased that the Light Study is now being terminated and want to thank the patients and all of those involved in the study. This trial has yielded important information about the safety profile for Contrave.
We have been informed that Takeda is on track to initiate a PMR cardiovascular outcomes trial (CVOT) later this year and recently achieved the first planned milestone with FDA acceptance of the study protocol in April.
Today some of the 50% interim analysis of the Light Study was disclosed by a third party. Because most of our management team remains blinded to the 50% data, we are unable to comment.
There have been a lot of challenges surrounding the use of interim data from ongoing studies for regulatory purposes. There are competing tensions for data confidentiality to preserve study integrity, transparency laws, and guidelines from regulatory bodies. With respect to the Light Study, Orexigen filed patent applications based on the unexpected result of the 25% interim analysis of LIGHT Study data. The first of those applications was granted and issued in March, and the full clinical study report that was submitted to FDA in the patent application was disclosed by the United States Patent and Trademark Office (USPTO).
A few articles on this topic have been published in the media today that include misleading statements about our company. Contrary to allegations cited today by a journalist, Orexigen has never misled patients. At the time of the patent issuance in March, we stated plainly and clearly that the effect of Contrave on CV morbidity and mortality has not been established and that a larger number of MACE are required to precisely determine the effect of Contrave on CV outcomes.
I bought in the dip today as well
I agree.
They are getting burned for the early leak!
Not very likely.
It's bad press but not dangerous med.
It was sloppy leak of info by parent company.
They need to start all over because they initially thought that there was a cardiovascular benefit. The second 25% of cohort showed no benefit CV-wise but it also did not show any CV concerns.
In the long run, OREX will be fine but the bad press is brutal
Stopped out today.
Horrible press
OREX
Stopped out at 6.64 from entry average at 4.82
Just too much bad press to push this higher
ONTY
Took a position here just now on a stock that has been beaten down lately but has ASCO potential EOM
Yes
But if the commodity prices go up significantly in the next 2 Q's, the shorts will start to cover which could sling shot this northward quickly.
Oversold because of the lawsuit noise which won't amount to anything.
Sales will continue to be the driver here in the end.
I agree 100%
Seems very oversold. I'm thinking that this could shoot the share price up quickly with a meaningful recovery in commodity pricing?
Yep
But I still don't get how a company grossing $220 million per year has a market cap of only $377 million.
Shouldn't we be trading around 3 times that?
Magnum Hunter 1Q Production 163.6 MMcfe/d >MHR *
Monday 05/11/2015 07:13 AM ET - Dow Jones News
Magnum Hunter 1Q Proved Reserves Up 73% to 869.2 Bcfe >MHR *
Monday 05/11/2015 07:13 AM ET - Dow Jones News
Magnum Hunter Sees 2015 Average Daily Production 180-204 MMcfe/d >MHR *
Monday 05/11/2015 07:12 AM ET - Dow Jones News
View more recent headlines
Good work getting back to even on that last flip.
BTW: did you see OREX had $11.5 million in net sales for the quarter on Contrave launch?
This is a $10 stock easily.
OREX
Orexigen 1Q-End Cash, Equivalents, Marketable Securities $188.6M *
Friday 05/08/2015 07:03 AM ET - Dow Jones News
Orexigen 1Q Contrave Net Sales $11.5M >OREX *
Friday 05/08/2015 07:02 AM ET - Dow Jones News